Sökning: onr:"swepub:oai:DiVA.org:uu-123155" >
Lithium trial in Al...
Lithium trial in Alzheimer's disease : a randomized, single-blind, placebo-controlled, multicenter 10-week study
-
Hampel, Harald (författare)
-
Ewers, Michael (författare)
-
Bürger, Katharina (författare)
-
visa fler...
-
- Annas, Peter (författare)
- Karolinska Institutet
-
Mörtberg, Anette (författare)
-
Bogstedt, Anna (författare)
-
Frölich, Lutz (författare)
-
Schröder, Johannes (författare)
-
Schönknecht, Peter (författare)
-
Riepe, Matthias W (författare)
-
Kraft, Inga (författare)
-
Gasser, Thomas (författare)
-
Leyhe, Thomas (författare)
-
Möller, Hans-Jürgen (författare)
-
Kurz, Alexander (författare)
-
- Basun, Hans (författare)
- Uppsala universitet,Geriatrik
-
visa färre...
-
(creator_code:org_t)
- 2009
- 2009
- Engelska.
-
Ingår i: Journal of Clinical Psychiatry. - 0160-6689 .- 1555-2101. ; 70:6, s. 922-931
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.4...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVE: Lithium, a first-line drug for the treatment of bipolar depression, has recently been shown to regulate glycogen synthase kinase-3 (GSK-3), a kinase that is involved in the phosphorylation of the tau protein. Since hyperphosphorylation of tau is a core pathological feature in Alzheimer's disease, lithium-induced inhibition of GSK-3 activity may have therapeutic effects in Alzheimer's disease. In the current study, we tested the effect of short-term lithium treatment in patients with Alzheimer's disease. METHOD: A total of 71 patients with mild Alzheimer's disease (Mini-Mental State Examination score > or = 21 and < or = 26) were successfully randomly assigned to placebo (N = 38) or lithium treatment (N = 33) at 6 academic expert memory clinics. The 10-week treatment included a 6-week titration phase to reach the target serum level of lithium (0.5-0.8 mmol/L). The primary outcome measures were cerebrospinal fluid (CSF) levels of phosphorylated tau (p-tau) and GSK-3 activity in lymphocytes. Secondary outcome measures were CSF concentration of total tau and beta-amyloid(1-42) (Abeta(1-42)), plasma levels of Abeta(1-42), Alzheimer's Disease Assessment Scale (ADAS)-Cognitive summary scores, MMSE, and Neuropsychiatric Inventory (NPI). Patients were enrolled in the study from November 2004 to July 2005. RESULTS: No treatment effect on GSK-3 activity or CSF-based biomarker concentrations (P > .05) was observed. Lithium treatment did not lead to change in global cognitive performance as measured by the ADAS-Cog subscale (P = .11) or in depressive symptoms. CONCLUSIONS: The current results do not support the notion that lithium treatment may lead to reduced hyperphosphorylation of tau protein after a short 10-week treatment in the Alzheimer's disease target population.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hampel, Harald
-
Ewers, Michael
-
Bürger, Katharin ...
-
Annas, Peter
-
Mörtberg, Anette
-
Bogstedt, Anna
-
visa fler...
-
Frölich, Lutz
-
Schröder, Johann ...
-
Schönknecht, Pet ...
-
Riepe, Matthias ...
-
Kraft, Inga
-
Gasser, Thomas
-
Leyhe, Thomas
-
Möller, Hans-Jür ...
-
Kurz, Alexander
-
Basun, Hans
-
visa färre...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet